In-theater advertising company National CineMedia Inc. is well-positioned to reap the benefits of cinema’s unique proposition ...

Wedbush raised the firm’s price target on Rubrik (RBRK) to $80 from $75 and keeps an Outperform rating on the shares. The firm notes Rubrik ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Investment analysts at Wedbush boosted their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a research ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to discuss outlooks on ...

Despite the recent rash of tech stock sell-offs, the analysts at Wedbush believe this is a short-term phenomenon, and the ...

Wedbush analysts called Palantir one of their "top names" to own in 2025, expecting the stock to benefit from a "tidal wave of spending on AI." ...

Elon Musk’s role in the Trump administration is complicating his business ventures, as the tech billionaire pushes forward with efforts to slash the federal government and budget in the face of ...